Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/1/2007
 
First Published:
8/1/2000
1.
Phase II Randomized Study of Radiotherapy With or Without Vaccination Comprising Recombinant Vaccinia-PSA and rV-B7.1 Plus Recombinant Fowlpox-PSA Vaccine in Patients With Localized Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
NCI-00-C-0154
NCI-NMOB-B00-021, NCI-894, 894, NCT00020228
Last Modified:
11/13/2007
 
First Published:
8/1/2000
2.
Phase II Randomized Study of Vaccine Containing Recombinant Vaccinia-Prostate-Specific Antigen (PSA) Admixed With rV-B7.1 Plus Recombinant Fowlpox-PSA Vaccine, Sargramostim (GM-CSF), and Interleukin-2 Versus Nilutamide Alone in Patients With Hormone-Refractory Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
NCI-00-C-0137
MB-NAVY-99-04, NCI-T99-0097, T99-0097, NCT00020254
Last Modified:
2/23/2006
 
First Published:
9/1/2002
3.
Phase II Pilot Randomized Study of Fowlpox (Pox Vector)-Prostate-Specific Antigen Vaccine With or Without Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
NCI-02-C-0218
NCI-5319, 5319, NCT00045227
Last Modified:
6/5/2006
 
First Published:
12/1/1999
4.
Phase I Study of Intralesional Recombinant rV-B7.1 Vaccine in Patients With Unresectable Metastatic Melanoma (Summary Last Modified 02/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
Over 18
NCI
AECM-99-101
NCI-T99-0006, NCT00004148, T99-0006
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute